Akari Therapeutics PLC (NASDAQ:AKTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Akari Therapeutics PLC (NASDAQ:AKTX) have earned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $32.3333.

AKTX has been the topic of a number of research reports. Maxim Group upgraded Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 price objective on the stock in a report on Monday, July 20th. Weiss Ratings raised Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, July 6th. Alliance Global Partners upgraded shares of Akari Therapeutics to a “strong-buy” rating in a research report on Friday. Finally, Wall Street Zen raised shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 22nd.

Akari Therapeutics Trading Up 2.4%

Shares of Akari Therapeutics stock opened at $9.38 on Tuesday. Akari Therapeutics has a fifty-two week low of $3.02 and a fifty-two week high of $49.60. The firm has a 50-day simple moving average of $9.26 and a two-hundred day simple moving average of $9.03.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression.

Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation.